Wave Life Sciences Ltd.

NasdaqGM:WVE Voorraadrapport

Marktkapitalisatie: US$2.2b

Wave Life Sciences Beheer

Beheer criteriumcontroles 3/4

De CEO Wave Life Sciences is Paul B. Bolno, benoemd in Dec2013, heeft een ambtstermijn van 10.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.87M, bestaande uit 16.4% salaris en 83.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.18% van de aandelen van het bedrijf, ter waarde $ 3.81M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.9 jaar en 8 jaar.

Belangrijke informatie

Paul B. Bolno

Algemeen directeur

US$3.9m

Totale compensatie

Percentage CEO-salaris16.4%
Dienstverband CEO10.9yrs
Eigendom CEO0.2%
Management gemiddelde ambtstermijn3.9yrs
Gemiddelde ambtstermijn bestuur8yrs

Recente managementupdates

Recent updates

Wave Life Sciences: Positive WVE-006 Data For AATD Leads To 2025 Catalyst

Oct 16

There's Reason For Concern Over Wave Life Sciences Ltd.'s (NASDAQ:WVE) Massive 43% Price Jump

Sep 25
There's Reason For Concern Over Wave Life Sciences Ltd.'s (NASDAQ:WVE) Massive 43% Price Jump

Wave Life Sciences: Spiking On Strong DMD Data, But Not Fully De-Risked Yet

Sep 24

Broker Revenue Forecasts For Wave Life Sciences Ltd. (NASDAQ:WVE) Are Surging Higher

Sep 08
Broker Revenue Forecasts For Wave Life Sciences Ltd. (NASDAQ:WVE) Are Surging Higher

We're Keeping An Eye On Wave Life Sciences' (NASDAQ:WVE) Cash Burn Rate

Aug 05
We're Keeping An Eye On Wave Life Sciences' (NASDAQ:WVE) Cash Burn Rate

Pinning Down Wave Life Sciences Ltd.'s (NASDAQ:WVE) P/S Is Difficult Right Now

Jun 25
Pinning Down Wave Life Sciences Ltd.'s (NASDAQ:WVE) P/S Is Difficult Right Now

We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth

Apr 09
We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth

Wave Life Sciences' Weighty Ambition: Carving Out Obesity Niche

Mar 09

Wave Life Sciences Ltd.'s (NASDAQ:WVE) 30% Price Boost Is Out Of Tune With Revenues

Mar 03
Wave Life Sciences Ltd.'s (NASDAQ:WVE) 30% Price Boost Is Out Of Tune With Revenues

We're Interested To See How Wave Life Sciences (NASDAQ:WVE) Uses Its Cash Hoard To Grow

Sep 13
We're Interested To See How Wave Life Sciences (NASDAQ:WVE) Uses Its Cash Hoard To Grow

Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Cut Their EPS Forecasts Substantially

May 08
Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Cut Their EPS Forecasts Substantially

Here's Why Wave Life Sciences (NASDAQ:WVE) Must Use Its Cash Wisely

Mar 30
Here's Why Wave Life Sciences (NASDAQ:WVE) Must Use Its Cash Wisely

Are Investors Undervaluing Wave Life Sciences Ltd. (NASDAQ:WVE) By 47%?

Jan 20
Are Investors Undervaluing Wave Life Sciences Ltd. (NASDAQ:WVE) By 47%?

Some Analysts Just Cut Their Wave Life Sciences Ltd. (NASDAQ:WVE) Estimates

Nov 11
Some Analysts Just Cut Their Wave Life Sciences Ltd. (NASDAQ:WVE) Estimates

Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Deliver On Growth Plans?

Aug 12
Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Deliver On Growth Plans?

Wave Life Sciences Q2 2022 Earnings Preview

Aug 10

Will Wave Life Sciences (NASDAQ:WVE) Spend Its Cash Wisely?

Apr 21
Will Wave Life Sciences (NASDAQ:WVE) Spend Its Cash Wisely?

Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Invest In Growth?

Jan 11
Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Invest In Growth?

We Think Wave Life Sciences (NASDAQ:WVE) Needs To Drive Business Growth Carefully

Sep 24
We Think Wave Life Sciences (NASDAQ:WVE) Needs To Drive Business Growth Carefully

Analyse CEO-vergoeding

Hoe is Paul B. Bolno's beloning veranderd ten opzichte van Wave Life Sciences's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$73m

Mar 31 2024n/an/a

-US$62m

Dec 31 2023US$4mUS$636k

-US$58m

Sep 30 2023n/an/a

-US$85m

Jun 30 2023n/an/a

-US$131m

Mar 31 2023n/an/a

-US$151m

Dec 31 2022US$3mUS$618k

-US$162m

Sep 30 2022n/an/a

-US$153m

Jun 30 2022n/an/a

-US$120m

Mar 31 2022n/an/a

-US$118m

Dec 31 2021US$4mUS$597k

-US$122m

Sep 30 2021n/an/a

-US$116m

Jun 30 2021n/an/a

-US$143m

Mar 31 2021n/an/a

-US$145m

Dec 31 2020US$1mUS$579k

-US$150m

Sep 30 2020n/an/a

-US$178m

Jun 30 2020n/an/a

-US$196m

Mar 31 2020n/an/a

-US$197m

Dec 31 2019US$4mUS$579k

-US$194m

Sep 30 2019n/an/a

-US$175m

Jun 30 2019n/an/a

-US$162m

Mar 31 2019n/an/a

-US$156m

Dec 31 2018US$6mUS$541k

-US$147m

Sep 30 2018n/an/a

-US$140m

Jun 30 2018n/an/a

-US$127m

Mar 31 2018n/an/a

-US$116m

Dec 31 2017US$3mUS$515k

-US$102m

Compensatie versus markt: De totale vergoeding ($USD 3.87M ) Paul B. } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.36M ).

Compensatie versus inkomsten: De vergoeding van Paul B. is gestegen terwijl het bedrijf verliesgevend is.


CEO

Paul B. Bolno (50 yo)

10.9yrs

Tenure

US$3,874,300

Compensatie

Dr. Paul B. Bolno, M.D., MBA served as an Independent Director at SQZ Biotechnologies Company since June 2020 until March 2024. Since May 2020 he has served as Chairman of the Scientific Advisory Group for...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Paul B. Bolno
President10.9yrsUS$3.87m0.18%
$ 3.8m
Kyle B. Moran
CFO & Principal Accounting Officer3.9yrsUS$1.70m0.029%
$ 635.7k
Chandra Vargeese
Chief Technology Officer4.5yrsUS$1.78m0.12%
$ 2.6m
Erik Ingelsson
Chief Scientific Officerless than a yeargeen gegevensgeen gegevens
Kate Rausch
Head of Investor Relations5.6yrsgeen gegevensgeen gegevens
Linda Rockett
Senior VP & General Counsel8.5yrsgeen gegevensgeen gegevens
Christopher Francis
Senior VP of Corporate Development & Head of Emerging Areas7.8yrsUS$1.68m0%
$ 0
Daryn Lewis
Senior VP & Head of Human Resources1.8yrsgeen gegevensgeen gegevens
Sridhar Vaddeboina
Senior Vice President of Chemistry3yrsgeen gegevensgeen gegevens
Anne-Marie Li-Kwai-Cheung
Chief Development Officer2.1yrsgeen gegevensgeen gegevens
Hsiu-Chiung Yang
Senior Vice President of Translational Medicine1.8yrsgeen gegevensgeen gegevens

3.9yrs

Gemiddelde duur

51.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van WVE wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Paul B. Bolno
President10.6yrsUS$3.87m0.18%
$ 3.8m
Gregory L. Verdine
Director11.3yrsUS$170.74k0.020%
$ 426.0k
Mark H. Corrigan
Independent Director5.2yrsUS$194.74k0.078%
$ 1.7m
Christian O. Henry
Independent Chairperson8yrsUS$222.24k0.085%
$ 1.8m
Adrian G. Rawcliffe
Independent Director7.8yrsUS$188.74k0.085%
$ 1.8m
Peter Kolchinsky
Independent Director9.8yrsUS$170.74k0%
$ 0
Ken Takanashi
Independent Director12.3yrsUS$170.74k0%
$ 0
Heidi L. Wagner
Independent Director5.2yrsUS$185.74k0.078%
$ 1.7m
Aik Na Tan
Independent Director4.3yrsUS$172.24k0.069%
$ 1.5m

8.0yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van WVE wordt beschouwd als ervaren (gemiddelde ambtstermijn 8 jaar).